- Report
- January 2022
- 42 Pages
Global
From €3566EUR$3,750USD£2,998GBP
- Report
- September 2021
- 144 Pages
China
From €3803EUR$4,000USD£3,198GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3803EUR$4,000USD£3,198GBP
- Report
- October 2023
- 253 Pages
Global
From €4706EUR$4,950USD£3,958GBP
- Report
- October 2023
- 150 Pages
Global
From €4611EUR$4,850USD£3,878GBP
- Report
- January 2024
- 200 Pages
Global
From €3946EUR$4,150USD£3,318GBP
- Report
- June 2023
- 115 Pages
Global
From €4279EUR$4,500USD£3,598GBP
- Report
- April 2024
- 80 Pages
Argentina
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Brazil
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
China
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
France
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Germany
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
India
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Ireland
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Japan
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Poland
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Russia
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1426EUR$1,500USD£1,199GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1426EUR$1,500USD£1,199GBP
From €1426EUR$1,500USD£1,199GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more